Morgan Stanley Sticks to Its Buy Rating for Thermo Fisher (TMO)
Morgan Stanley analyst Kallum Titchmarsh reiterated a Buy rating on Thermo Fisher yesterday and set a price target of $670.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Titchmarsh is a 4-star analyst with an average return of 9.7% and a 50.00% success rate. Titchmarsh covers the Healthcare sector, focusing on stocks such as Danaher, Stevanato Group, and Thermo Fisher.
Currently, the analyst consensus on Thermo Fisher is a Strong Buy with an average price target of $675.79, a 14.12% upside from current levels. In a report released today, Citi also maintained a Buy rating on the stock with a $685.00 price target.
Based on Thermo Fisher’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $12.22 billion and a net profit of $1.97 billion. In comparison, last year the company earned a revenue of $11.4 billion and had a net profit of $1.83 billion
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMO in relation to earlier this year. Last month, Michel Lagarde, the EVP & COO of TMO sold 22,046.00 shares for a total of $12,424,243.76.
Read More on TMO:
Disclaimer & DisclosureReport an Issue
- Private Markets: Nvidia, Microsoft consider new investment in OpenAI
- Thermo Fisher price target raised to $615 from $590 at UBS
- Thermo Fisher price target raised to $653 from $645 at Baird
- Thermo Fisher price target raised to $685 from $660 at Citi
- Thermo Fisher price target raised to $650 from $625 at Barclays
